(Q44923637)

7 December 2017

title

Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management (English)

1 reference

7 December 2017

1 reference

1 reference

2

1 reference

7 December 2017

3

1 reference

7 December 2017

6

K Rajender Reddy

1 reference

7 December 2017

Stephen H Caldwell

1

1 reference

7 December 2017

B Gail Macik

4

1 reference

7 December 2017

Patrick G Northup

5

1 reference

7 December 2017

Armando Tripodi

7

1 reference

7 December 2017

Arun J Sanyal

8

1 reference

7 December 2017

Coagulation in Liver Disease Group

9

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 October 2006

1 reference

7 December 2017

1 reference

7 December 2017

volume

44

1 reference

7 December 2017

issue

4

1 reference

7 December 2017

page(s)

1039-1046

1 reference

Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000.

7 December 2017

cites work

1 reference

7 January 2021

Newer concepts of blood coagulation

1 reference

7 January 2021

Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials

1 reference

7 January 2021

Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation

1 reference

7 January 2021

Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests

1 reference

7 January 2021

A cell-based model of hemostasis

1 reference

7 January 2021

Existence of a platelet-adhesion defect in patients with cirrhosis independent of hematocrit: studies under flow conditions

1 reference

7 January 2021

Endothelial dysfunction in cirrhosis and portal hypertension

1 reference

7 January 2021

Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity

1 reference

7 January 2021

Factor VIII expression in liver disease.

1 reference

7 January 2021

Acquired dysfibrinogenaemia in liver disease

1 reference

7 January 2021

Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis

1 reference

7 January 2021

A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis

1 reference

7 January 2021

Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit

1 reference

7 January 2021

Activation of coagulation after administration of tumor necrosis factor to normal subjects

1 reference

7 January 2021

Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study.

1 reference

7 January 2021

Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis

1 reference

7 January 2021

Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis

1 reference

7 January 2021

Infection and hemostasis in decompensated cirrhosis: a prospective study using thrombelastography

1 reference

7 January 2021

Infection, coagulation, and variceal bleeding in cirrhosis

1 reference

7 January 2021

Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease

1 reference

7 January 2021

Disseminated intravascular coagulation in liver cirrhosis: fact or fiction?

1 reference

7 January 2021

AICF and DIC in liver cirrhosis: expressions of a hypercoagulable state

1 reference

7 January 2021

AASLD position paper: the management of acute liver failure

1 reference

7 January 2021

Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting

1 reference

7 January 2021

Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients

1 reference

7 January 2021

Bleeding time in patients with cirrhosis: relation with degree of liver failure and clotting abnormalities

1 reference

7 January 2021

Complications of cirrhosis: is endothelium guilty?

1 reference

7 January 2021

Bleeding after liver biopsy does not correlate with indices of peripheral coagulation

1 reference

7 January 2021

Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage

1 reference

7 January 2021

Assessment of blood coagulation in severe liver disease using thromboelastography: use of citrate storage versus native blood

1 reference

7 January 2021

Meeting transfusion safety expectations

1 reference

7 January 2021

Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantation

1 reference

7 January 2021

Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study

1 reference

7 January 2021

Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review

1 reference

7 January 2021

The efficacy and safety of epsilon-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis.

1 reference

7 January 2021

Natural anticoagulants and the liver

1 reference

7 January 2021

Hepatic arterial resistance in cirrhosis with and without portal vein thrombosis: relationships with portal hemodynamics.

1 reference

7 January 2021

Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism

1 reference

7 January 2021

Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis

1 reference

7 January 2021

Relation between lupus anticoagulant and splanchnic venous thrombosis in cirrhosis of the liver

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21303

1 reference

7 December 2017

1 reference